{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:46:46Z","timestamp":1791712006665,"version":"4.3.4"},"reference-count":87,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10160","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T05:23:19Z","timestamp":1414560199000},"page":"e0026","source":"Crossref","is-referenced-by-count":17,"title":["ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies"],"prefix":"10.5041","volume":"5","author":[{"given":"Galit","family":"Sarig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","unstructured":"1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.","journal-title":"N Engl J Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.ki.5001535","article-title":"The molecular biology of thrombotic microangiopathy","volume":"70","author":"Tsai","year":"2006","unstructured":"2. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006;70:16-23.","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1111\/j.1538-7836.2005.01425.x","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"L\u00e4mmle","year":"2005","unstructured":"3. L\u00e4mmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005;3:1663-75.","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1055\/s-0032-1306431","article-title":"Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management","volume":"38","author":"Tsai","year":"2012","unstructured":"4. Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012;38:469-82.","journal-title":"Semin Thromb Hemost"},{"key":"ref4","unstructured":"5. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924;24:1."},{"key":"ref5","unstructured":"6. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 1955;85: 905-9."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"JD Jr","year":"1978","unstructured":"7. Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978;298: 1350-2.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","unstructured":"8. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-5.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/infdis\/151.5.775","article-title":"The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli","volume":"151","author":"Karmali","year":"1985","unstructured":"9. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985;151: 775-82.","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","unstructured":"10. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-34.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","unstructured":"11. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87: 4235-44.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","article-title":"Purification of von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family","volume":"98","author":"Fujikawa","year":"2001","unstructured":"12. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-6.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood.V98.6.1654","article-title":"Partial amino acid sequence of purified von Willebrand factor-cleaving protease","volume":"98","author":"Gerritsen","year":"2001","unstructured":"13. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001;98:1654-61.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","unstructured":"14. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413: 488-94.","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"11902","DOI":"10.1073\/pnas.172277399","article-title":"Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity","volume":"99","author":"Kokame","year":"2002","unstructured":"15. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002;99: 11902-7.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1365-2141.2003.04183.x","article-title":"ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13","volume":"120","author":"Antoine","year":"2003","unstructured":"16. Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003;120:821-4.","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytepenic purpura","volume":"91","author":"Furlan","year":"1998","unstructured":"17. Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytepenic purpura. Blood 1998;91:2839-46.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"HM","year":"1998","unstructured":"18. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1055\/s-0034-1383547","article-title":"Thrombotic microangiopathies and the linkage between von Willebrand Factor and the alternative complement pathway","volume":"40","author":"Turner","year":"2014","unstructured":"19. Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic microangiopathies and the linkage between von Willebrand Factor and the alternative complement pathway. Semin Thromb Hemost 2014; 40:544-50.","journal-title":"Semin Thromb Hemost"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1172\/JCI112736","article-title":"Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation","volume":"78","author":"Moake","year":"1986","unstructured":"20. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986;78:1456-61.","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1182\/blood-2001-11-0060","article-title":"Ultra-large multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet GP Ib-IX complex: studies using optical tweezers","volume":"99","author":"Arya","year":"2002","unstructured":"21. Arya M, Anvari B, Romo GM, et al. Ultra-large multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet GP Ib-IX complex: studies using optical tweezers. Blood 2002;99: 3971-7.","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004: 407-23.","DOI":"10.1182\/asheducation-2004.1.407"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.beha.2009.07.004","article-title":"Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies","volume":"22","author":"Moake","year":"2009","unstructured":"23. Moake J. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 2009;22:567-76.","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1182\/blood-2005-05-2029","article-title":"Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions","volume":"106","author":"Tao","year":"2005","unstructured":"24. Tao Z, Peng Y, Nolasco L, et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005;106:4139-45.","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"29633","DOI":"10.1074\/jbc.M301385200","article-title":"ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor","volume":"278","author":"Dong","year":"2003","unstructured":"25. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003;278:29633-9.","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1752-8062.2009.00142.x","article-title":"Thrombotic microangiopathies: multimers, metalloprotease, and beyond","volume":"2","author":"Moake","year":"2009","unstructured":"26. Moake J. Thrombotic microangiopathies: multimers, metalloprotease, and beyond. Clin Transl Sci 2009;2: 366-73.","journal-title":"Clin Transl Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","unstructured":"27. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142:819-26.","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1046\/j.1365-2141.2000.01941.x","article-title":"Management of thrombotic thrombocytopenic purpura","volume":"109","author":"Rock","year":"2000","unstructured":"28. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000;109:496-507","journal-title":"Br J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-2006-939763","article-title":"Thrombotic thrombocytopenic purpura-then and now","volume":"32","author":"Galbusera","year":"2006","unstructured":"29. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenic purpura-then and now. Semin Thromb Hemost 2006;32:81-9.","journal-title":"Semin Thromb Hemost"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5482\/HAMO-13-04-0026","article-title":"Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry","volume":"2","author":"Mansouri Taleghani","year":"2013","unstructured":"30. Mansouri Taleghani M, von Krogh A-S, Fujimura Y, et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. H\u00e4mostaseologie 2013;2:138-43.","journal-title":"H\u00e4mostaseologie"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/j.1538-7836.2012.04852.x","article-title":"A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom","volume":"10","author":"Camilleri","year":"2012","unstructured":"31. Camilleri RS, Scully M, Thomas M, et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012;10:1792-801.","journal-title":"J Thromb Haemost"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2141.2006.06264.x","article-title":"The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura","volume":"135","author":"Scully","year":"2006","unstructured":"32. Scully M, Gattens M, Khair K, Liesner R. The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2006; 135:101-4.","journal-title":"Br J Haematol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/01.mph.0000135284.85292.2c","article-title":"Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency","volume":"26","author":"Schiff","year":"2004","unstructured":"33. Schiff DE, Roberts WD, Willert J, Tsai HM. Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency. J Pediatr Hematol Oncol 2004;26:535-8.","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1055\/s-2006-939764","article-title":"Thrombotic thrombocytopenic purpura associated with von Willebrand factor cleaving protease (ADAMTS13) deficiency in children","volume":"32","author":"Loirat","year":"2006","unstructured":"34. Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D. Thrombotic thrombocytopenic purpura associated with von Willebrand factor cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost 2006;32:90-7.","journal-title":"Semin Thromb Hemost"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2013.11.004","article-title":"Thrombotic microangiopathies","volume":"43","author":"Rosove","year":"2014","unstructured":"35. Rosove MH. Thrombotic microangiopathies. Semin Arthritis Rheum 2014;43:797-805.","journal-title":"Semin Arthritis Rheum"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","unstructured":"36. Scully M, Hunt BJ, Benjamin S, et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158:323-35.","journal-title":"Br J Haematol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","unstructured":"37. Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012;120:440-8.","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","unstructured":"38. Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012;119:588-97.","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"Furlan","year":"1997","unstructured":"39. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89:3097-103.","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","unstructured":"40. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood-2002-08-2399","article-title":"von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP","volume":"101","author":"Schneppenheim","year":"2003","unstructured":"41. Schneppenheim R, Budde U, Oyen F, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003;101:1845-50.","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011;9(Suppl 1):283-301.","DOI":"10.1111\/j.1538-7836.2011.04341.x"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","unstructured":"43. Terrell DR, Williams LA, Vesely SK, L\u00e4mmle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005;3:1432-6.","journal-title":"J Thromb Haemost"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/jca.20226","article-title":"Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience","volume":"25","author":"Douglas","year":"2010","unstructured":"44. Douglas KW, Pollock KG, Young D, Catlow J, Green R. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J Clin Apher 2010;25: 47-53.","journal-title":"J Clin Apher"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00062752-200309000-00003","article-title":"The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"10","author":"George","year":"2003","unstructured":"45. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003;10:339-44.","journal-title":"Curr Opin Hematol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","unstructured":"46. Kremer Hovinga JA, Vesely SK, Terrell DR, L\u00e4mmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500-11.","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenia purpura-hemolytic uremic syndrome-clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","unstructured":"47. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenia purpura-hemolytic uremic syndrome-clinical experience in 108 patients. N Engl J Med 1991;325:398-403.","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","article-title":"Cognitive deficits after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Kennedy","year":"2009","unstructured":"48. Kennedy AS, Lewis QF, Scott JG, et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009;49:1092-101.","journal-title":"Transfusion"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","unstructured":"49. Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013;122:2023-9.","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpurahemolytic uremic syndrome","volume":"116","author":"George","year":"2010","unstructured":"50. George JN. How I treat patients with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Blood 2010;116:4060-9.","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome","volume":"36","author":"Mele","year":"2014","unstructured":"51. Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420.","journal-title":"Semin Immunopathol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1182\/blood-2005-05-2111","article-title":"Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers","volume":"106","author":"Nolasco","year":"2005","unstructured":"52. Nolasco LH, Turner NA, Bernardo A, et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005;106:4199-209.","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","article-title":"Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany","volume":"365","author":"Frank","year":"2011","unstructured":"53. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011;365:1771-80.","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","unstructured":"54. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676-87.","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"55. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008;75:1-8.","DOI":"10.1016\/j.mvr.2007.04.009"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0301-2115(03)00199-4","article-title":"Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies","volume":"111","author":"Ducloy-Bouthors","year":"2003","unstructured":"56. Ducloy-Bouthors AS, Caron C, Subtil D, et al. Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies. Eur J Obstet Gynecol Reprod Biol 2003;111:146-52.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/01.mbc.0000240918.65306.20","article-title":"Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura","volume":"17","author":"Scully","year":"2006","unstructured":"57. Scully M, Starke R, Lee R, Mackie I, Machin S, Cohen H. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006;17:459-63.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1055\/s-0032-1328894","article-title":"Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR)","volume":"38","author":"Jacob","year":"2012","unstructured":"58. Jacob S, Dunn BL, Qureshi ZP, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012;38:845-53.","journal-title":"Semin Thromb Hemost"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jacc.2007.04.093","article-title":"Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project","volume":"50","author":"Bennett","year":"2007","unstructured":"59. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007;50:1138-43.","journal-title":"J Am Coll Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"794","DOI":"10.7326\/0003-4819-132-10-200005160-00005","article-title":"Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura","volume":"132","author":"Tsai","year":"2000","unstructured":"60. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794-9.","journal-title":"Ann Intern Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF02982073","article-title":"Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity","volume":"74","author":"Sugio","year":"2001","unstructured":"61. Sugio Y, Okamura T, Shimoda K, et al. Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol 2001;74: 347-51.","journal-title":"Int J Hematol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","unstructured":"62. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007;92:95-100.","journal-title":"Haematologica"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000046589","article-title":"Thrombotic microangiopathy in the cancer patient","volume":"106","author":"HC","year":"2001","unstructured":"63. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haematol 2001;106:52-6.","journal-title":"Acta Haematol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1046\/j.1365-2141.2001.02704.x","article-title":"Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease","volume":"113","author":"Fontana","year":"2001","unstructured":"64. Fontana S, Gerritsen HE, Kremer HJ, Furlan M, Lammle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 2001;113:100-2.","journal-title":"Br J Haematol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1538-7836.2010.03761.x","article-title":"ADAMTS-13 assays in thrombotic thrombocytopenic purpura","volume":"8","author":"Peyvandi","year":"2010","unstructured":"65. Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8: 631-40.","journal-title":"J Thromb Haemost"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1055\/s-0030-1248727","article-title":"Methodologies and clinical utility of ADAMTS-13 activity testing","volume":"36","author":"Just","year":"2010","unstructured":"66. Just S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost 2010;36:82-90.","journal-title":"Semin Thromb Hemost"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/j.1538-7836.2008.03099.x","article-title":"Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13)","volume":"6","author":"Tripodi","year":"2008","unstructured":"67. Tripodi A, Peyvandi F, Chantarangkul V, et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008;6:1534-41.","journal-title":"J Thromb Haemost"},{"key":"ref67","unstructured":"68. External Quality Control for Assays and Tests with a Focus on Thrombosis and Haemostasis. 2014-2 survey report. ECAT Foundation. July 30, 2014. Accessible to registered users via http:\/\/www.ecat.nl\/"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura","volume":"102","author":"Scheiflinger","year":"2003","unstructured":"69. Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003;102:3241-3.","journal-title":"Blood"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ajh.20097","article-title":"Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma","volume":"76","author":"Knovich","year":"2004","unstructured":"70. Knovich MA, Craver K, Matulis MD, Lawson H, Owen J. Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma. Am J Hematol 2004;76:286-90.","journal-title":"Am J Hematol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura","volume":"100","author":"Bianchi","year":"2002","unstructured":"71. Bianchi V, Robles R, Alberio L, Furlan M, L\u00e4mmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002;100:710-13.","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","unstructured":"72. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fr\u00e9meaux-Bacchi V. French Study Group for aHUS\/ C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-57.","journal-title":"Nat Rev Nephrol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.blre.2009.11.001","article-title":"Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application","volume":"24","author":"Scully","year":"2010","unstructured":"73. Scully M. Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application. Blood Rev 2010;24:11-16.","journal-title":"Blood Rev"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"74. Kappers-Klunne MC, van Asten JG, van Vliet HH. ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism? Ann Hematol 2009;88:1025-8.","DOI":"10.1007\/s00277-009-0709-7"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2141.2006.06471.x","article-title":"The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura","volume":"136","author":"Starke","year":"2006","unstructured":"75. Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol 2006;136:649-55.","journal-title":"Br J Haematol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MOP.0b013e32835e7888","article-title":"Thrombotic thrombocytopenic purpura in children","volume":"25","author":"Loirat","year":"2013","unstructured":"76. Loirat C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura in children. Curr Opin Pediatr 2013;25:216-24.","journal-title":"Curr Opin Pediatr"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"77. Scully M. Rituximab in the treatment of TTP. Hematology 2012;17(Suppl 1):S22-4.","DOI":"10.1179\/102453312X13336169155178"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","unstructured":"78. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008;93: 232-9.","journal-title":"Haematologica"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1053\/j.seminhematol.2011.08.004","article-title":"Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura","volume":"48","author":"SR","year":"2011","unstructured":"79. Cataland SR, Wu HM. Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura. Semin Hematol 2011; 48:242-50.","journal-title":"Semin Hematol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1538-7836.2012.04808.x","article-title":"ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura","volume":"10","author":"Bettoni","year":"2012","unstructured":"80. Bettoni G, Palla R, Valsecchi C, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012;10: 1556-65.","journal-title":"J Thromb Haemost"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","unstructured":"81. Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012;119:6128-35.","journal-title":"Blood"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","unstructured":"82. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011;9:936-44.","journal-title":"J Thromb Haemost"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","unstructured":"83. Jian C, Xiao J, Gong L, et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012;119:3836-43.","journal-title":"Blood"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","unstructured":"84. Cataland SR, Peyvandi F, Mannucci PM, et al. Initial experience from a double blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 2012;87:430-2.","journal-title":"Am J Hematol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","unstructured":"85. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012; 120:3603-10.","journal-title":"Blood"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1182\/blood-2012-04-421248","article-title":"Inhibition of von Willebrand factor platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons","volume":"120","author":"Feys","year":"2012","unstructured":"86. Feys HB, Roodt J, Vandeputte N, et al. Inhibition of von Willebrand factor platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood 2012;120:3611-14.","journal-title":"Blood"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"12","author":"Chen","year":"2011","unstructured":"87. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011;12:593-603.","journal-title":"J Clin Invest"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/416\/1\/PublishFiles\/436Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:01:12Z","timestamp":1791709272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/23\/Articles\/436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,29]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10160","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}